Ashar Luqman, MD
Nephrology · Sioux City, IANPI 1275742090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,275 of the $56,237 with a category attached, or 64.5%. 38 manufacturers reported payments, led by Travere Therapeutics, Inc. at 48.6% of the total. Among nephrology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $121.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$27K
- Vifor Pharma, Inc.$17K
- Boehringer Ingelheim$3K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Lilly USA, LLC$1K
- Amgen$963
- plus $5K from 32 others
Across 82 payments — averaging $12,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$621K
- Bayer$248K
- Amgen$72K
- Aurinia Pharma U.S., Inc.$66K
- CSL Behring$48K
- Boehringer Ingelheim International GmbH$624
- plus $392 from 1 others
What the payments were for
- Consulting fees$4,9509%
- Speaking & faculty fees$36,27565%
- Travel & lodging$6,32811%
- Food & beverage$8,55815%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,237 in reported general payments places this provider in the 95th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,315 | $852,908 |
| JardianceEmpagliflozin | 571 | $451,587 |
| JanuviaSitagliptin Phosphate | 211 | $135,394 |
| OzempicSemaglutide | 92 | $93,790 |
| KerendiaFinerenone | 111 | $78,225 |
| Cinacalcet Hcl | 687 | $76,620 |
| RybelsusSemaglutide | 25 | $47,827 |
| VelphoroSucroferric Oxyhydroxide | 12 | $43,312 |
| MyrbetriqMirabegron | 100 | $38,947 |
| EliquisApixaban | 58 | $37,535 |
| TradjentaLinagliptin | 59 | $34,482 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $32,129 |
| Bumetanide | 1,302 | $31,385 |
| Potassium Chloride | 1,594 | $30,475 |
| TrulicityDulaglutide | 21 | $30,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Pulmicort Flexhaler | $524 | $878,3251,405 claims |
| Boehringer IngelheimJardiance, Tradjenta | $3,099 | $486,069630 claims |
| Novo NordiskOzempic, Rybelsus | $277 | $141,617117 claims |
| MerckJanuvia | $29 | $135,394211 claims |
| BayerKerendia | $386 | $78,225111 claims |
| Fresenius USA Marketing, Inc.Velphoro | $610 | $43,31212 claims |
| PfizerEliquis | $13 | $37,53558 claims |
| Lilly USA, LLCTrulicity | $1,110 | $30,33621 claims |
| NovartisEntresto | $97 | $24,41619 claims |
| Sanofi-aventis U.S. LLCRenvela | $53 | $11,80119 claims |
| GSKTrelegy Ellipta | $13 | $8,69514 claims |
| Johnson & JohnsonProcrit | $29 | $7,38514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 nephrology providers in Iowa.
Other nephrology in Sioux City
- Jerold ErlandsonSioux City$3K
- Sharon FeySioux City$2K
- Min-Hwa ChowSioux City$313
- Craig ShadurDes Moines$314K
- Andrew BlandDubuque$76K
- Lawrence HunsickerIowa City$70K
- Jeremy PepinCouncil Bluffs$42K
- Prem ChandranDes Moines$19K
- Lama NoureddineIowa City$7K
- Benjamin GriffinIowa City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.